Zymeworks Q3 2025 revenue $27.6M, net loss narrows to $19.6M; positive ZW191 data

Zymeworks Inc.

2025-Q3 EPS reported -$0.53 revenue$103,450,000

Revenue $27.6M (up from $16.0M YoY) driven by $25.0M J&J milestone; net loss $19.6M vs $29.9M.
Cash resources $299.4M as of Sep 30, 2025; projected runway into 2H-2027 including anticipated milestones.
Encouraging Phase 1 data for ZW191 (FRα ADC): 53% objective response rate (64% in gynecological cancers).
First patient dosed in Phase 1 trial of ZW251 (GPC3-targeting ADC) for hepatocellular carcinoma.
Completed $22.7M in share repurchases (1.44M shares at avg $15.80) under remaining $30.0M program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.